Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/217705
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality |
Otros títulos: | MM, SARS-CoV-2 infection, and inpatient mortality | Autor: | Martínez-López, Joaquín; Mateos, Maria Victoria; Encinas, Cristina; Sureda, Anna; Hernández-Rivas, José Ángel; López de la Guía, Ana; Conde, Diego; Krsnik, Isabel; Prieto, Elena; Riaza Grau, Rosalía; Gironella, Mercedes; Blanchard, María Jesús; Caminos, Nerea; Fernández de Larrea, Carlos; Senin, María Alicia; Escalante, Fernando; Puerta, José Enrique de la; Gimenez, Eugenio; Martínez-Barranco, Pilar; Mateos, Juan José; Casado, Luis Felipe; Bladé, Joan; Lahuerta, Juan José; Cruz, Javier de la; San-Miguel, Jesús | Fecha de publicación: | 30-jun-2020 | Editor: | MedRxiv | Resumen: | There is limited information on the characteristics, pre-admission prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with coronavirus disease 2019 (COVID-19). This retrospective case series investigated characteristics and outcomes of 167 MM patients hospitalized with COVID-19 reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in Spain between March 1 and April 30, 2020. Outcomes were compared with a randomly selected contemporary cohort of 167 age-/sex-matched non-cancer patients with COVID-19 admitted at 6 participating hospitals. Common demographic, clinical, laboratory, treatment, and outcome variables were collected; specific disease status and treatment data were collected for MM patients. Among the MM and non-cancer patients, median age was 71 years and 57% of patients were male in each series, and 75% and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate-severe in 77% and 89% of patients and critical in 8% and 4%, respectively. Supplemental oxygen was required by 47% and 55% of MM and non-cancer patients, respectively, and 21%/9% vs 8%/6% required non-invasive/invasive ventilation. Inpatient mortality was 34% and 23% in MM and non-cancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors of inpatient mortality on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19. | Versión del editor: | https://doi.org/10.1101/2020.06.29.20142455 | URI: | http://hdl.handle.net/10261/217705 | DOI: | 10.1101/2020.06.29.20142455 |
Aparece en las colecciones: | (IBMCC) Artículos (PTI Salud Global) Colección Especial COVID-19 |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Multiple Myeloma_MartinezLopez.pdf | 544,05 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
Page view(s)
130
checked on 28-mar-2024
Download(s)
126
checked on 28-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons